3RD FLOOR, ALTRINCHAM, CHESHIRE, X0
Other Events
Annual Report to Security Holders
Ex-99.1
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Amended material disclosure
Announces CEO Transition as Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Centessa Pharmaceuticals Enters Amended Sales Agreement with Leerink
Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
Q1
FY 2025
Q3
Q2
FY 2024
Amended Quarterly Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Merger Proxy Statement
Definitive Proxy Statement
Additional Proxy Materials
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
PREM14A
Correspondence
Submission Upload
S-1MEF
SEC Staff Correspondence